Announcement time of this financial report: 2023-10-25 16:31:31

Wushi (Stock Code: 300357) is a company operating in the biomedical industry, dedicated to the development and production of high-quality biomedical products. The company adheres to the concept of innovation and research and development, has advanced technology and equipment, and maintains close cooperation with scientific research institutions and partners at home and abroad. In terms of policy changes in China's pharmaceutical industry, companies actively respond to and constantly improve their R & D capabilities and product quality in order to adapt to changes in market demand.

First of all, in terms of assets and liabilities, our total assets in the third quarter of 2023 were 2.511 billion yuan, compared with 2.198 billion yuan at the end of last year, an increase of 14.23%. The total debt was 243 million yuan, an increase of 42.11% compared with 171 million yuan at the end of last year. The net asset was 2.268 billion yuan, an increase of 11.89% compared with 2.027 billion yuan at the end of last year. The asset-liability ratio was 9.67%, up from 7.77% at the end of last year. These changes are mainly due to factors such as the transfer of the completion acceptance of the company's new plant to fixed assets and the temporary increase in project payment due to the completion settlement of projects under construction.

Secondly, in terms of profit, Wushi's operating income in the third quarter of 2023 was 674 million yuan, down 3.77% from 700 million yuan in the same period last year. Operating profit was 301 million yuan, down 20% from 376 million yuan in the same period last year. Net profit was 260 million yuan, down 18.5% from 319 million yuan in the same period last year. These changes are mainly due to a decrease in total profits due to a decrease in government subsidies related to day-to-day operating activities and a decrease in the company's operating income and other income.

Thirdly, in terms of cash flow, the net cash flow generated by our operating activities in the third quarter of 2023 was 251 million yuan, compared with 250 million yuan in the same period last year, a slight increase. Cash inflows from operating activities totaled 694 million yuan, down from 717 million yuan in the same period last year. Cash outflow from operating activities totaled 442 million yuan, down from 467 million yuan in the same period last year.

To sum up, Wushi's business situation in the third quarter of 2023 is generally stable, but its profits have declined to a certain extent. In the future operation, the company needs to further improve its R & D capabilities and product quality to adapt to changes in market demand, but also need to actively respond to changes in industry policies in order to maintain the sustainable development of the company.

For investors, Wushi, as a member of the biomedical industry, has a good development prospect. However, in view of the decline in the company's net profit, investors should fully consider the risk and make careful decisions when investing.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.